Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Emvenio Research

Neither a doctor nor a teaching hospital

Research payments

$1,725,593

363 payments

Through program year 2025, Emvenio Research is reported as receiving $1,725,593 in research payments, across 363 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $120,858 336
2024 Research $390,610 14
2023 Research $1,214,125 13

Breakdown

Who paid Research payments · program years 2023–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $815,551 43 payments
  2. Merck Sharp & Dohme Corporation $732,002 4 payments
  3. Boehringer Ingelheim International GmbH $83,420 307 payments
  4. AstraZeneca UK Limited $43,619 2 payments
  5. GlaxoSmithKline, LLC. $29,750 5 payments
  6. AstraZeneca Pharmaceuticals LP $21,250 2 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-na Adults 18 to 64 years of Age With Increased Risk for Pneumococcal Disease $692,809 1 payment
  2. Phase III efficacy for obesity without T2DM $261,973 6 payments
  3. phase III efficacy for obesity with T2DM $259,343 6 payments
  4. Phase III efficacy for obesity - without T2DM $207,127 6 payments
  5. phase III efficacy for obesity - with T2DM $145,392 6 payments
  6. Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) $49,149 3 payments
  7. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-na ve Adults 18 to 64 years of Age With Increased Risk for Pneumococcal Disease $38,091 2 payments
  8. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multic $29,750 5 payments
  9. A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event $15,720 1 payment
  10. A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes $14,850 180 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record